BeStock  
Stocks › Biotechnology › CRVS

Corvus Pharmaceuticals CRVS

US equityMarket cap rank #3290Biotechnology
$9.67 −$0.34 (-3.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.67 0.00%
Open$9.84
Prev close$10.01
Day range$9.56 – $10.04
Volume927.5K
Market cap$815.69M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$21.36M-102.1% YoY
Net profit-$20.34M-100.3% YoY
Diluted EPS-$0.22-83.3% YoY
Free cash flow-$12.28M-28.4% YoY
Operating cash flow-$12.22M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-12.1MDec '24$15.2MMar '25$-8.0MJun '25$-10.2MSep '25$-12.3MDec '25$-13.7MMar '26$-18.0MJun '26$-20.3MSep '26

Diluted EPS by quarter

-0.18Dec '24-0.13Mar '25-0.10Jun '25-0.12Sep '25-0.15Dec '25-0.15Mar '26-0.19Jun '26-0.22Sep '26

Free cash flow by quarter

$-8.5MDec '24$-8.3MMar '25$-5.9MJun '25$-9.6MSep '25$-9.2MDec '25$-10.5MMar '26$-16.0MJun '26$-12.3MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-45.9%
Return on assets-42.3%
Return on invested capital-50.2%
Current ratio13.38
Liabilities / assets6.9%
Cash & investments$202.95M
Total debt$139,000.00
Net cash (debt)$202.81M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $21.36M $19.30M $14.88M $42.97M $12.22M
Selling and Admin Expenses $3.58M $3.33M $3.70M $9.25M $2.28M
-General & Admin Expense $3.58M $3.33M $3.70M $9.25M $2.28M
Research & Development $17.78M $15.96M $11.18M $33.72M $9.94M
Operating Profit -$21.36M -$19.30M -$14.88M -$42.97M -$12.22M
Net Non-Operating Interest Income (Expense) $1.91M $2.05M $1.78M $2.51M $603,000.00
Non-Operating Interest Income $1.91M $2.05M $1.78M $2.51M $603,000.00
Other Income (Expense) -$891,000.00 -$709,000.00 -$599,000.00 $25.18M -$707,000.00
Earnings from Equity Interest -$891,000.00 -$709,000.00 -$599,000.00 -$1.96M -$707,000.00
Pretax Profit -$20.34M -$17.96M -$13.69M -$15.28M -$12.32M
Net Profit -$20.34M -$17.96M -$13.69M -$15.28M -$12.32M
Profit from Continuing Operations -$20.34M -$17.96M -$13.69M -$15.28M -$12.32M
Net Income to Parent Company -$20.34M -$17.96M -$13.69M -$15.28M -$12.32M
Net Income to Common Stockholders -$20.34M -$17.96M -$13.69M -$15.28M -$12.32M
Basic EPS -$0.22 -$0.19 -$0.15 -$0.19 -$0.15
Diluted EPS -$0.22 -$0.19 -$0.15 -$0.53 -$0.15
Gain on Sale of Security – – – $27.14M $0.00
Special Income (Charges) – – – $0.00 –
-Gain on Sale of Property/Plant/Equipment – – – $0.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $223.88M $239.27M $253.20M $71.12M $71.12M
Total Current Assets $206.35M $220.97M $239.95M $58.21M $58.21M
Cash and Cash Equivalents & Short-Term Investments $202.95M $215.23M $236.71M $56.75M $56.75M
-Cash and Cash Equivalents $15.01M $18.91M $40.10M $4.58M $4.58M
-Short Term Investments $187.93M $196.32M $196.61M $52.17M $52.17M
Receivables $1.29M $1.85M $1.20M $374,000.00 $374,000.00
-Accounts Receivable $5,000.00 $6,000.00 $43,000.00 $37,000.00 $37,000.00
-Accrued Interest Receivable $1.28M $1.84M $1.16M $337,000.00 $337,000.00
Prepaid Assets $1.80M $3.31M $1.67M $772,000.00 $772,000.00
Other Current Assets $317,000.00 $575,000.00 $367,000.00 $318,000.00 $318,000.00
Total Non-Current Assets $17.53M $18.31M $13.25M $12.91M $12.91M
Net PPE $1.36M $1.49M $1.03M $1.06M $1.06M
-Gross PPE $4.17M $4.20M $3.71M $3.71M $3.71M
-Accumulated Depreciation -$2.81M -$2.71M -$2.68M -$2.65M -$2.65M
Investments and Advances $14.47M $15.11M $10.50M $10.99M $10.99M
-Long Term Equity Investment $14.47M $15.11M $10.50M $10.99M $10.99M
Other Non-Current Assets $1.70M $1.71M $1.72M $855,000.00 $855,000.00
Total Liabilities $15.56M $13.95M $12.52M $9.91M $9.91M
Total Current Liabilities $15.42M $13.67M $12.11M $9.38M $9.38M
Payables $5.65M $4.05M $4.70M $2.49M $2.49M
-Accounts Payable $5.65M $4.05M $4.70M $2.49M $2.49M
Current Accrued Expenses $7.06M $6.94M $5.40M $5.61M $5.61M
Short-Term Debt and Capital Lease Obligation $493,000.00 $454,000.00 $428,000.00 $403,000.00 $403,000.00
-Current Capital Lease Obligation $493,000.00 $454,000.00 $428,000.00 $403,000.00 $403,000.00
Other Current Liabilities $367,000.00 $299,000.00 $206,000.00 $238,000.00 $238,000.00
Total Non-Current Liabilities $139,000.00 $274,000.00 $406,000.00 $534,000.00 $534,000.00
Long Term Debt and Capital Lease Obligation $139,000.00 $274,000.00 $406,000.00 $534,000.00 $534,000.00
-Long Term Capital Lease Obligation $139,000.00 $274,000.00 $406,000.00 $534,000.00 $534,000.00
Total Equity $208.32M $225.33M $240.68M $61.21M $61.21M
Stockholders' Equity $208.32M $225.33M $240.68M $61.21M $61.21M
Capital Stock $8,000.00 $8,000.00 $8,000.00 $7,000.00 $7,000.00
-Common Stock $8,000.00 $8,000.00 $8,000.00 $7,000.00 $7,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $674.19M $670.56M $667.78M $474.39M $474.39M
Retained Earnings -$464.29M -$443.94M -$425.99M -$412.29M -$412.29M
Gains/Losses Not Affecting Retained Earnings -$1.59M -$1.29M -$1.13M -$896,000.00 -$896,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$12.22M -$15.40M -$10.37M -$32.80M -$9.19M
Net cash flow from continuing operations -$12.22M -$15.40M -$10.37M -$32.80M -$9.19M
Net Income from Continuing Operations -$20.34M -$17.96M -$13.69M -$15.28M -$12.32M
Gain/Loss from Continuing Operations $891,000.00 $709,000.00 $599,000.00 -$25.18M $707,000.00
Depreciation & Depletion & Amortization $95,000.00 $34,000.00 $29,000.00 $105,000.00 $26,000.00
Change in Working Capital $4.06M -$976,000.00 $57,000.00 $3.58M $1.08M
-Change in Receivables $1,000.00 $37,000.00 -$6,000.00 $38,000.00 -$5,000.00
-Change in Prepaid Assets $2.34M -$2.54M -$1.76M $941,000.00 -$204,000.00
-Change in Payables and Accrued Expense $1.71M $1.54M $2.71M $2.67M $1.28M
-Change in Other Current Assets $106,000.00 $99,000.00 -$777,000.00 $115,000.00 $85,000.00
-Change in Other Current Liabilities -$96,000.00 -$106,000.00 -$103,000.00 -$185,000.00 -$74,000.00
Net cash flow from investing $7.52M -$5.97M -$144.85M -$7.80M $10.88M
Net Cash Flow from Continuing Investing Activities $7.52M -$5.97M -$144.85M -$7.80M $10.88M
Net PPE Purchase and Sale -$66,000.00 -$582,000.00 -$91,000.00 -$174,000.00 -$25,000.00
Net Business Purchase and Sale $0.00 – – – –
Net Investment Purchase and Sale $7.58M -$383,000.00 -$144.76M -$7.62M $10.91M
Financing Cash Flow $805,000.00 $166,000.00 $190.75M $36.43M $20,000.00
Net Cash Flow from Continuing Financing Activities $805,000.00 $166,000.00 $190.75M $36.43M $20,000.00
Net Common Stock Issuance $0.00 $0.00 $189.41M $0.00 $0.00
Proceeds from Stock Option Exercised $805,000.00 $166,000.00 $1.34M $36.43M $20,000.00
Ending Cash Balance $15.01M $18.91M $40.10M $4.58M $4.58M
Net Change in Cash -$3.89M -$21.20M $35.53M -$4.16M $1.71M
Beginning Cash Balance $18.91M $40.10M $4.58M $8.74M $2.87M
Free Cash Flow -$12.28M -$15.98M -$10.47M -$32.97M -$9.22M

Discussion

No comments yet — be the first to weigh in on CRVS.

Sign in to join the discussion.

Scroll to Top